Holen Sie sich die Stockscreener-App
1.60
4.76%
-0.08
Handel nachbörslich:
1.61
0.01
+0.63%
Schlusskurs vom Vortag:
$1.68
Offen:
$1.68
24-Stunden-Volumen:
2.38M
Relative Volume:
1.98
Marktkapitalisierung:
$98.22M
Einnahmen:
$5.03M
Nettoeinkommen (Verlust:
$-185.41M
KGV:
-0.5178
EPS:
-3.09
Netto-Cashflow:
$-139.79M
1W Leistung:
-5.33%
1M Leistung:
+13.48%
6M Leistung:
-51.37%
1J Leistung:
-86.96%
1-Tages-Spanne:
$1.55
$1.71
1-Wochen-Bereich:
$1.54
$1.745
52-Wochen-Spanne:
$1.1001
$16.10
Pliant Therapeutics Inc Stock (PLRX) Company Profile
Firmenname
Pliant Therapeutics Inc
Sektor
Branche
Telefon
650-481-6770
Adresse
331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
Vergleichen Sie PLRX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PLRX
Pliant Therapeutics Inc
|
1.60 | 103.13M | 5.03M | -185.41M | -139.79M | -3.09 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Pliant Therapeutics Inc Stock (PLRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-04 | Fortgesetzt | Cantor Fitzgerald | Neutral |
| 2025-03-04 | Herabstufung | Needham | Buy → Hold |
| 2025-03-03 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2025-03-03 | Herabstufung | Stifel | Buy → Hold |
| 2025-02-10 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2025-02-10 | Herabstufung | Citigroup | Buy → Neutral |
| 2025-02-10 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2025-02-10 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2025-02-10 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2025-02-10 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-02-10 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-09-09 | Fortgesetzt | Leerink Partners | Outperform |
| 2023-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2023-05-18 | Eingeleitet | Canaccord Genuity | Buy |
| 2023-04-13 | Eingeleitet | Robert W. Baird | Outperform |
| 2022-12-14 | Eingeleitet | Stifel | Buy |
| 2022-12-07 | Eingeleitet | JP Morgan | Overweight |
| 2022-09-01 | Eingeleitet | Citigroup | Buy |
| 2022-07-20 | Eingeleitet | SVB Leerink | Outperform |
| 2022-05-25 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-12-10 | Eingeleitet | Oppenheimer | Outperform |
| 2021-11-24 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-11-03 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-04-20 | Eingeleitet | BTIG Research | Buy |
| 2021-04-05 | Eingeleitet | Citigroup | Buy |
| 2020-06-29 | Eingeleitet | Citigroup | Buy |
| 2020-06-29 | Eingeleitet | Cowen | Outperform |
| 2020-06-29 | Eingeleitet | Needham | Buy |
| 2020-06-29 | Eingeleitet | Piper Sandler | Overweight |
Alle ansehen
Pliant Therapeutics Inc Aktie (PLRX) Neueste Nachrichten
Is Pliant Therapeutics Inc. a defensive stockMarket Volume Summary & Free High Accuracy Swing Entry Alerts - thegnnews.com
Citi Maintains Pliant Therapeutics(PLRX.US) With Hold Rating, Maintains Target Price $1.7 - 富途牛牛
Citi Raises Pliant Therapeutics Price Target to $1.70 Amid Unclear Path Forward - AInvest
Healthcare Sector Analysts Weigh In on Sangamo Biosciences, Pliant Therapeutics, and Zimmer Biomet Holdings - AInvest
Citi Reaffirms Their Hold Rating on Pliant Therapeutics (PLRX) - The Globe and Mail
A Quick Look at Today's Ratings for Pliant Therapeutics(PLRX.US), With a Forecast Between $1.7 to $4 - 富途牛牛
Pliant Therapeutics Pivots To Oncology After Ending IPF Program - Finimize
Pliant Therapeutics shares fall 1.25% intraday after workforce realignment and BEACON-IPF closure. - AInvest
RBC Capital Maintains Pliant Therapeutics(PLRX.US) With Hold Rating, Maintains Target Price $3 - 富途牛牛
Pliant Therapeutics stock price target slashed by Piper Sandler - Investing.com Canada
Needham Maintains Pliant Therapeutics(PLRX.US) With Hold Rating - 富途牛牛
Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results - 富途牛牛
Pliant Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Pliant Therapeutics reports Q2 EPS (71c), consensus (68c) - TipRanks
Pliant Therapeutics Q2 net loss narrows - MarketScreener
Pliant Therapeutics reports Q2 FY25 financial results, Phase 1 oncology trial on track. - AInvest
Pliant Therapeutics Discontinues Key IPF Drug Trial, Pivots Focus to Promising Oncology Program - Stock Titan
Pliant Therapeutics shares rise 2.65% intraday after IDEAYA Biosciences reports positive Phase 2/3 trial data. - AInvest
Should I hold or sell Pliant Therapeutics Inc. stock in 2025Tremendous financial leverage - Jammu Links News
Pliant Therapeutics Inc. Stock Analysis and ForecastRapidly expanding wealth - Jammu Links News
How many analysts rate Pliant Therapeutics Inc. as a “Buy”Identify undervalued stocks ready to soar - Jammu Links News
A Quick Look at Today's Ratings for Pliant Therapeutics(PLRX.US), With a Forecast Between $3 to $17 - 富途牛牛
How volatile is Pliant Therapeutics Inc. stock compared to the marketDiscover hidden gems in the stock market - Jammu Links News
How does Pliant Therapeutics Inc. compare to its industry peersInvest confidently with market-leading analysis - Jammu Links News
Is Pliant Therapeutics Inc. a good long term investmentInvest confidently with expert support - Jammu Links News
Does Pliant Therapeutics Inc. stock perform well during market downturnsAchieve rapid portfolio growth with expert guidance - Jammu Links News
What is the risk reward ratio of investing in Pliant Therapeutics Inc. stockGame-changing returns - Jammu Links News
What makes Pliant Therapeutics Inc. stock price move sharplyFree Stock Market Return Analysis - Jammu Links News
What are Pliant Therapeutics Inc. company’s key revenue driversDiscover undervalued opportunities early - Jammu Links News
What is Pliant Therapeutics Inc. company’s growth strategyBuild wealth steadily with smart stock selection - Jammu Links News
Pliant Therapeutics Inc. Trading Near Value Zone — Recovery AheadTop Performing Stock Insights Released Daily - metal.it
What are analysts’ price targets for Pliant Therapeutics Inc. in the next 12 monthsAdvanced Screener Planner For 2025 - Jammu Links News
Competitive Positioning of Pliant Therapeutics Inc.: Is It Leading or LaggingWeekly Return Pick Forecast Reports Show Trend - metal.it
Published on: 2025-07-30 01:15:54 - metal.it
Bollinger Bands Expand on Pliant Therapeutics Inc. — Volatility AheadWatchlist for Smart Swing Trading Updated - beatles.ru
Will Pliant Therapeutics Inc. stock split in the near futureInvestment Playbook for Growing Markets Shared - metal.it
Pliant Therapeutics Inc. Sees Spike in Bullish Option FlowDaily Momentum Screener With Alerts Launched - metal.it
What catalysts could drive Pliant Therapeutics Inc. stock higher in 2025Unprecedented profit potential - Jammu Links News
Pliant Therapeutics Inc. Added to High Probability Setup ListLow Risk High Return Opportunities Identified - metal.it
What is the dividend policy of Pliant Therapeutics Inc. stockFree Trading Psychology Coaching - Jammu Links News
Is it the right time to buy Pliant Therapeutics Inc. stockHigh-octane financial growth - jammulinksnews.com
Finanzdaten der Pliant Therapeutics Inc-Aktie (PLRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):